Cipla inks MoU with Russian firm for HIV, Hepatitis C drugs

20 Jun 2016 Evaluate

Cipla, a global pharmaceutical company has signed a Memorandum of Understanding (MoU) with Russia’s National Immunobiological Company to innovative antiviral medical products for HIV and Hepatitis C treatment and to technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1320.35 -7.90 (-0.59%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×